As drugmakers prepare for the government to stop paying for their COVID-19 treatments, the value of Pfizer’s popular COVID-19 drug Paxlovid has decreased by more than 80 percent, according to the Institute for Clinical and Economic Review.
Read the full post on Becker's Hospital Review - Healthcare News
